EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

ZBTB16 controls the onset of Clostridium difficile colitis through the Pyrin inflammasome

Shuhui Li, Jingjing He, Huxidanmu Tuoheniyazi, Junrui Ma, Zhenyu Li, Juanjuan Zheng, Yuxin Wang, Xiupan Gao, Xiaobao Yang, Danping Liu, Yanan Zhao, Tongxuan Su und 3 weitere

Pharmacological Research · 2026

DOI: 10.1016/j.phrs.2026.108133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Research, 2026. Verfasst von Shuhui Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China; College of Health Scie…. Hauptthemen laut MEDLINE: Inflammasomes, Pyrin, Clostridioides difficile, Colitis. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shanghai Jiao Tong University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clostridium difficile infection (CDI) is a leading cause of antibiotic-associated diarrhea and pseudomembranous colitis, and there remains a significant unmet need for therapies specifically targeting C. difficile . The Pyrin inflammasome, activated by bacterial toxins, plays a critical role in driving macrophage-mediated intestinal inflammation during CDI. In this study, we report that myeloid-specific deficiency of Zbtb16 protects mice from C. difficile -induced colitis by attenuating IL-1β-dependent inflammatory signaling. Mechanistic studies revealed that Zbtb16 deletion disrupts ASC oligomerization and speck formation, thereby selectively inhibiting inflammasome assembly and reducing mature IL-1β production in macrophages stimulated with C. difficile culture supernatant or purified TcdB toxin. Importantly, pharmacological degradation of ZBTB16 using the cereblon E3 ligase modulating drug CC-3060 significantly ameliorated colitis severity in a murine model of CDI. Our findings establish ZBTB16 as a key regulator of Pyrin inflammasome activation in macrophages, highlighting the therapeutic promise of ZBTB16 degradation as a novel strategy for treating CDI. • Myeloid ZBTB16 is identified as a critical activator of the Pyrin inflammasome during Clostridium difficile infection (CDI). • Deficiency in ZBTB16 impairs inflammasome assembly and IL-1β secretion by suppressing ASC oligomerization and speck formation. • Pharmacological degradation of ZBTB16 using the cereblon modulator CC-3060 reduces inflammasome activation and ameliorates colitis in a murine model of CDI. • Targeting ZBTB16 represents a promising therapeutic approach for mitigating C. difficile-associated inflammatory pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InflammasomesPyrinClostridioides difficileColitisEnterocolitis, PseudomembranousAnimalsMacrophagesMice, Inbred C57BLMiceMice, KnockoutInterleukin-1betaColon

Stichwörter der Autor:innen

ASCClostridium difficileColitisInflammasomeZBTB16

Substanzen

InflammasomesPyrinInterleukin-1beta

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China; College of Health Sciences and Technology, Shanghai Jiao Tong University School of Medicine,…
  • Blood Transfusion Department, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, 253000, China. Electronic address: dzzhengjuanjuan@163.com.

Förderung

  • Shanghai Jiao Tong University
  • National Natural Science Foundation of China

Zitieren

APA

Li, S., He, J., Tuoheniyazi, H., Ma, J., Li, Z., Zheng, J., Wang, Y., Gao, X., Yang, X., Liu, D., Zhao, Y., Su, T., Peng, Y., Xu, D., & Fei, X. (2026). ZBTB16 controls the onset of Clostridium difficile colitis through the Pyrin inflammasome. Pharmacological Research. https://doi.org/10.1016/j.phrs.2026.108133

Vancouver

Li S, He J, Tuoheniyazi H, Ma J, Li Z, Zheng J, et al. ZBTB16 controls the onset of Clostridium difficile colitis through the Pyrin inflammasome. Pharmacological Research. 2026. doi:10.1016/j.phrs.2026.108133

BibTeX
@article{Li2026,
  author = {Li, Shuhui and He, Jingjing and Tuoheniyazi, Huxidanmu and Ma, Junrui and Li, Zhenyu and Zheng, Juanjuan and Wang, Yuxin and Gao, Xiupan and Yang, Xiaobao and Liu, Danping and Zhao, Yanan and Su, Tongxuan and Peng, Yibing and Xu, Dakang and Fei, Xuefeng},
  title = {ZBTB16 controls the onset of Clostridium difficile colitis through the Pyrin inflammasome},
  journal = {Pharmacological Research},
  year = {2026},
  doi = {10.1016/j.phrs.2026.108133}
}
Kostenlos starten →